Royalty asked ELN shareholders in its statement on February 25 to decide if they want to remain invested in a company that will consist of cash and the Tysabri Royalty, "... while Elan's management pursues its announced strategy." They encouraged shareholders to sell their shares to Royalty for a cash amount that Royalty Pharma believes reflects the full value of Elan today. It won't be an easy decision either way.
The whole drama here reflects what an enormous prize the intellectual property and patents of the biopharmaceutical companies are worth. Right now ELN shareholders and potential shareholders know that what they own (mainly the Tysabri Royalties) is valued for at least $11-a-share.
Now if we continue our sleuthing and find the next undervalued and overlooked biopharmaceutical company with products and patents worth a small fortune, we may be able to experience what ELN shareholders are enjoying. Might that be a company like Amarin (AMRN)? Stay tuned.DISCLOSURE: As of the time of publication the author was not long any of the shares of companies mentioned in this article. Jim Cramer and Stephanie Link actively manage a real money portfolio for his charitable trust- enjoy advance notice of every trade, full access to the portfolio, and deep coverage of the latest economic events and market movements. Follow @m8a2r1
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts